Download PDF
Thromb Haemost 1982; 47(02): 150-153
DOI: 10.1055/s-0038-1657151
Original Article
Schattauer GmbH Stuttgart

Inhibition of Platelet Function by Antiarrhythmic Drugs, Verapamil and Disopyramide

P Han
*   The School of Applied Science, Canberra College of Advanced Education, Canberra, ACT., Australia
,
C Boatwright
The Department of Medicine and Clinical Science, The John Curtin School of Medical Research, The Australian National University, Australia
,
N G Ardlie
The Department of Medicine and Clinical Science, The John Curtin School of Medical Research, The Australian National University, Australia
› Author Affiliations
Further Information

Publication History

Received 26 January 1982

Accepted 22 February 1982

Publication Date:
13 July 2018 (online)

Also available at
 PDF Download  Permissions and Reprints

Summary

Various cardiovascular drugs such as nitrates and propranolol, used in the treatment of coronary artery disease have been shown to have an antiplatelet effect. We have studied the in vitro effects of two antiarrhythmic drugs, verapamil and disopyramide, and have shown their inhibitory effect on platelet function. Verapamil, a calcium channel blocker, inhibited the second phase of platelet aggregation induced by adenosine diphosphate (ADP) and inhibited aggregation induced by collagen. Disopyramide similarly inhibited the second phase of platelet aggregation caused by ADP and aggregation induced by collagen. Either drug in synergism with propranolol inhibited ADP or collagen-induced platelet aggregation. Disopyramide at high concentrations inhibited arachidonic add whereas verapamil was without effect. Verapamil, but not disopyramide, inhibited aggregation induced by the ionophore A23187.

Key words

Platelet inhibition - Verapamil - Disopyramide - Propranolol
 

  • References

  • 1 Schafer AI, Handin RI. The role of platelets in thrombotic and vascular disease. Prog Cardiovasc Dis 1979; 22: 31-52
    CrossrefPubMedSearch in Google Scholar
  • 2 Weksler B, Gillick M, Pink J. Effect of propranolol on platelet function. Blood 1977; 49: 185-196
    PubMedSearch in Google Scholar
  • 3 Schafer AI, Alexander BW, Handin RI. Inhibition of platelet function by organic nitrate vasodilators. Blood 1980; 55: 649-654
    PubMedSearch in Google Scholar
  • 4 Han P, Genton E, Turpie AGG, Hirsh J, Gent M. Correlation between platelet survival, β-thromboglobulin and platelet aggregate ratio in patients with coronary artery disease. (Abstract) Circulation Part II 1978; 58: 116
    PubMedSearch in Google Scholar
  • 5 Green LH, Seroppian E, Handin RI. Platelet activation during exercise-induced myocardial ischaemia. N Engl J Med 1980; 302: 193-197
    CrossrefPubMedSearch in Google Scholar
  • 6 Maseri A, L’Abbate A, Baroldi G. Coronary spasm as a possible cause of myocardial infarction: A conclusion derived from study of “preinfarction” angina. N Engl J Med 1978; 299: 1271-1277
    CrossrefPubMedSearch in Google Scholar
  • 7 Lewy RI, Smith JB, Silver MJ, Wiener L, Walinsky P. Detection of thromboxane B2 in peripheral blood of patients with Prinzmetal’s angina. Prostaglandins and Medicine 1979; 2: 243-248
    CrossrefPubMedSearch in Google Scholar
  • 8 Mehta P, Mehta J. Platelet function studies in coronary heart disease: VIII. Decreased platelet sensitivity to prostacyclin in patients with myocardial ischaemia. Thromb Res 1980; 18: 273-277
    CrossrefPubMedSearch in Google Scholar
  • 9 Ikeda Y, Kikuchi M, Toyama K, Watanabe K, Ando Y. Inhibition of human platelet functions by verapamil. Thromb Haemostas 1981; 45: 158-161
    PubMedSearch in Google Scholar
  • 10 Haeusler G. Differential effect of verapamil on exdtadon-contraction coupling in smooth muscle and on excitation-secretion coupling in adrenergic nerve terminals. J Pharmacol Exp Ther 1972; 180: 672-682
    PubMedSearch in Google Scholar
  • 11 Nayler WG. The parmacology of disopyramide. J Int Med Res 1976; 4 (Suppl. 01) 8-12
    PubMedSearch in Google Scholar